3 results
Approved WMOCompleted
To determine the pharmacokinetic properties of a new elacridar formulation
Approved WMOCompleted
The primary objective of this study is to obtain clinical proof of principle that the addition of a PgP/BCRP inhibitor increases CNS concentrations of tyrosine kinase inhibitors by inhibition of drug efflux transporter function in the blood brain…
Approved WMOPending
The primary objective is to influence amygdala and ventral striatum neuronal activity, thereby changing their influence on consequent approach/avoidance decisions, as indicated with left or right button presses.